NASDAQ · Health care

Neumora Therapeutics, Inc. (NMRA)

It posted a net loss of $212.7M. At June 30, 2026 it held $116.8M in cash against $52.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.

Price

$0.68

-3.63% on the day · September 25, 2026

52-week range $0.63 to $3.65

Market cap

$127.3M

What Neumora Therapeutics, Inc. does

Neumora Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker NMRA.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$241.2M	-$236.9M	-$1.45	n/a
2024	n/a	-$263.5M	-$243.8M	-$1.53	n/a
2023	n/a	-$252.1M	-$235.9M	-$3.63	-$163.4M
2023	n/a	-$135.9M	-$130.9M	-$4.81	-$115.4M

Next report expected around November 5, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 6, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Neumora Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 14, 2026
Quarterly report 10-Q · period to June 30, 2026
August 14, 2026
Quarterly results 8-K
July 27, 2026
Other event 8-K
June 15, 2026
Material agreement 8-K
May 29, 2026
Shareholder vote results 8-K
May 15, 2026
Passive stake changed SCHEDULE 13G/A
May 7, 2026
Quarterly report 10-Q · period to March 31, 2026
May 7, 2026
Quarterly results 8-K
May 4, 2026
Passive stake changed SCHEDULE 13G/A
April 17, 2026
Additional proxy material DEFA14A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 21, 2026. Insider transactions on SEC

Insider trades

What the people running Neumora Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about NMRA

What does Neumora Therapeutics, Inc. do?

Neumora Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker NMRA.

Is Neumora Therapeutics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $212.7M.

When did Neumora Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 21, 2026.

Similar companies

AMGN

Amgen Inc

GILD

Gilead Sciences, Inc.

Neurocrine Biosciences Inc

EXEL

Exelixis, Inc.

Compare NMRA with

Compare NMRA with any company

Follow NMRA

Get an email when Neumora Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow NMRA: get an email when it files

Where the numbers come from

Financial figures are the values Neumora Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.